Anti-CD1d1 Antibody, clone 3G23 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Antigen-presenting glycoprotein CD1d1 (UniProt: P11609; also known as CD1d.1) is encoded by the Cd1d1 (also known as Cd1.1) gene (Gene ID: 12479) in murine species. CD1d is a transmembrane glycoprotein, part of the CD1 family of 5 antigen presenting molecules, that are related to Major histocompatibility complex class I (MHC-I) and II (MHC-II) molecules. The CD1 family is subdivided into group 1 (CD1a, CD1b, CD1c and CD1e) and group 2 (CD1d) based on sequence homology. CD1d mediates the presentation of lipid and glycolipid antigens derived from self or microbial sources to natural killer T (NKT) cells, which play a crucial role in immune responses. These antigens are presented via heterodimers formed with beta-2 microglobulin. CD1d is predominantly localized to late endosomes and lysosomes, facilitated by a tyrosine-based motif in its cytoplasmic tail, which enables intracellular trafficking. The protein is involved in both innate and adaptive immunity, particularly in regulating inflammatory responses through interactions with invariant NKT cells. CD1d expression is group-enriched in the intestine, liver, and lymphoid tissues, with enhanced expression observed in specific cell types such as Kupffer cells, macrophages, Hofbauer cells, and monocytes, underscoring its role in lipid antigen presentation and immune surveillance. CD1d has been implicated in diseases such as glioblastoma, where its expression correlates with immune system activity, and it is considered a potential therapeutic target in NKT cell-based cancer immunotherapy. CD1d expression is prognostic in certain lung cancers and adenocarcinoma. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Ogg, G., et al., (2019) Curr. Opin. Immunol, 59:121-129;  Evans, L., and Barral, P., (2024), Mol. Immunol, 170, 1-8)

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 18 amino acids from the N-terminal extracellular domain of mouse CD1d1.

Quality Control Testing
Evaluated by Western Blotting in RAW 264.7 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CD1d1 in RAW 264.7 cell lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CD1d1 in EL4 cell lysate and mouse thymus tissue lysate and a 1:10,000 dilution in rat thymus tissue lysate.
Affinity Binding Assay: A representative lot of this antibody bound with CD1d1 peptide with at least one million-fold (1,000,000X) higher affinity than with non-specific control peptide.

Flow Cytometry Analysis: 1 µg from a representative lot detected CD1d1 in one million C57BL6 mouse splenocytes.

Immunocytochemistry Analysis : A 1:100 dilution from a representative lot detected CD1d1 in RAW 264.7 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 3G23 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects mouse CD1d1. It targets an epitope within 18 amino acids from the N-terminal extracellular domain.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.